Senator Boudreau’s bill lets LDH set Medicaid criteria for FDA‑approved weight‑loss drugs; amendments adopted

Senator Boudreau introduced Senate Bill 433 and the committee adopted a package of technical and policy amendments before moving the measure as amended.

The bill directs the Louisiana Department of Health to establish coverage criteria for FDA‑approved weight‑loss medications for Medicaid members; Secretary of LDH, Secretary Greenstein, told the committee the department will limit eligibility to those most likely to benefit and will aggressively negotiate manufacturer rebates to control costs. "This is one of the few times I'm very excited about looking at the expansion of any Medicaid service," Greenstein said, adding that LDH already spends "about $240,000,000 today on GLP‑1s for our 1,481,000 Medicaid members." He said the department will monitor take‑up, side‑effect‑related drop‑off and the so‑called "woodwork effect" where previously eligible patients seek care once coverage is expanded.

Supporters framed the bill as a health and fiscal balancing act. Senator Boudreau said the measure "establishes the framework to address obesity within the Medicaid population while still preserving implementation authority for the Department of Health." The sponsor asked the committee to adopt amendments that refine eligibility criteria and guard against unbudgeted growth.

Senator Cloud raised concerns about compounded formulations used by some patients because those versions can be far cheaper than manufacturer products. "Some compounded versions with properly sourced ingredients are significantly cheaper right now," Cloud said, noting a constituent who pays about $150 per month for a compounded preparation versus much higher retail prices. Secretary Greenstein responded that LDH does not cover compounded drugs today and that they would not be included in current rebate agreements, but said LDH would model the financial effects of any policy change.

Committee members pressed LDH on outcomes to track and on whether coverage might extend to younger age groups now that the FDA has cleared some drugs for minors; Greenstein said the department will include FDA‑approved age indications when it sets coverage criteria and will report monitoring data back to the committee.

The committee accepted witness cards from hospitals, advocacy groups and registrants who provided information and support. After adopting the amendment set, the committee moved and reported SB 433 as amended for further floor action.

The next steps are for LDH to finalize eligibility rules under the adopted amendments and for the bill to proceed through the Senate floor and the House. The department committed to return to the committee with monitoring metrics and financial modeling.